At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
REGE procombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment
In Brief
A clinical study evaluating REGE pro for Psoriasis. Completed, enrolled 22 participants across 1 site.
Detailed Summary
Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving Psoriasis Area and Severity Index (PASI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
Primary CompletionFeb 2016
Study CompletionApr 2016
First PostedFeb 2018
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartAug 4, 2015
Primary CompletionFeb 13, 2016
Study CompletionApr 8, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.4 years ago
Interventions
REGE procombination
REGE pro is a patch of human amniotic membrane sterilized by gamma radiation